| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $17.2M | — | +27.1% |
| SG&A Expense | $4.0M | — | -10.1% |
| Operating Income | -$21.2M | — | -17.9% |
| Net Income | -$39.0M | — | -500.8% |
| EPS (Basic) | -$0.33 | — | -312.5% |
| EPS (Diluted) | -$0.33 | — | -312.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.2M | -73.0% | -27.6% |
| Short-term Investments | $104.9M | -5.1% | -9.8% |
| Current Assets | $113.6M | -16.3% | -11.1% |
| Total Assets | $146.7M | -13.2% | -9.1% |
| Current Liabilities | $13.5M | -26.6% | +46.5% |
| Total Liabilities | $46.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$22.6M | — | -40.8% |
| Investing Cash Flow | $6.0M | — | +53.0% |
| Financing Cash Flow | $115K | — | +0.0% |
| -1.1% |
| Stockholders' Equity | $44.8M | -44.8% | -60.9% |